Please read and agree to the
terms and conditions
of this site.
I agree
Medical Technology
/tech
Clear filters and search
Format
photo
Tags
boston blog main
boston top stories
crispr-cas9
4
×
life sciences
national
4
×
national blog main
national top stories
san francisco blog main
san francisco top stories
biotech
boulder/denver blog main
boulder/denver top stories
cancer
detroit blog main
detroit top stories
fda
new york blog main
new york top stories
raleigh-durham blog main
raleigh-durham top stories
roche
san diego blog main
san diego top stories
seattle blog main
seattle top stories
texas blog main
texas top stories
vertex pharmaceuticals
wisconsin blog main
wisconsin top stories
cancer immunotherapy
clinical trials
crispr
crispr therapeutics
deals
editas medicine
eidos therapeutics
eli lilly
gene editing
glaxosmithkline
What
crispr
roundup
bio
cancer
cas
days
medicine
potential
today
ahead
alliance
ambien
american
annual
asco
attendees
attention
big
biotech
bosley's
bosley’s
bridge
bristol
bucks
buy
calls
camp’s
cash
cells
ceo
changing
chicago
city
clinical
color
combinations
community’s
crime
defect
departure
Language
unset
Current search:
crispr-cas9
×
national
×
@xconomy.com
3 years ago
Bio Roundup: CRISPR Kudos, Bristol Myers’s Buy, RNAi Alliance & More
@xconomy.com
5 years ago
Bio Roundup: Bosley’s Editas Exit, Bridge Bucks, CRISPR Crime & More
@xconomy.com
5 years ago
CRISPR Risks? Researchers Stoke Fears of Cancer in Gene-Edited Cells
@xconomy.com
5 years ago
Biotech Roundup: ASCO Ahead, CAMP4’s Cash, Ambien Tweeting & More
